Ribon is backed by prominent life science investors, including Abbvie Ventures, Celgene, The Column Group, Deerfield Management, Johnson & Johnson Innovation, Novartis Venture Fund, Osage University Partners, Takeda Ventures, and U.S. Venture Partners.
AbbVie Ventures is the strategic investment arm of AbbVie, the global biopharmaceutical company. A core component of AbbVie’s integrated approach to external innovation, we invest in very early stage transformational scientific opportunities that augment AbbVie’s core R&D areas within oncology, immunology and neurodegenerative diseases. We work closely with management teams of portfolio companies to support them in executing on their development goals to achieve the best outcomes. For more information, please visit: https://www.abbvie.com/
Celgene is a global biopharmaceutical company focused on discovery, development and commercialization of innovative therapies for patients with cancer, immune-inflammatory and other unmet medical needs.
The Column Group (TCG) is a science-driven venture capital firm that makes significant financial and operational commitments to build early stage drug discovery companies based on their unique scientific platforms and potential to deliver multiple breakthrough therapeutics.
Deerfield’s approach to capital funding is uniquely flexible, giving companies the leverage they need to advance their business goals and set new standards for the healthcare industry.
Johnson & Johnson Innovation – JJDC Inc. (JJDC) is the strategic venture capital arm of Johnson & Johnson and a long-term investment partner to global healthcare entrepreneurs. Founded in 1973, JJDC continues a legacy of customizing deals for data-driven companies across the continuum of healthcare, with the goal of turning great ideas into transformative new pharmaceutical, medical device and consumer healthcare products. Visit our website at www.jjdc.com
Novartis Venture Fund is a financially driven corporate life science venture fund whose purpose is to foster innovation, drive significant patient benefit and generate superior returns by creating and investing in innovative life science companies at various stages of their development. For more information, please visit www.nvfund.com.
Osage University Partners (OUP) is a venture capital fund that invests exclusively in startups that are commercializing university research.
Takeda Ventures, Inc. (TVI) is the corporate venture arm of Takeda Pharmaceutical Company Limited (TPC) a world-class pharmaceutical company and the largest in Japan. TVI (formerly Takeda Research Investment, Inc.), was founded in 2001 with the vision to extend Takeda’s reach into the Global scientific community and forge strategic relationships that complement and expand internal R&D capabilities. Our aim to encourage and support therapeutic innovation in the biopharmaceutical sector, as well as academic centers of excellence, through early stage capital investment and the provision of access to the resources of a multinational pharmaceutical company.
U.S. Venture Partners’ mission is simple – to help entrepreneurs build great companies. For more than 30 years, we have partnered with entrepreneurs, who, like us, define “greatness” as having a major positive impact on industries, customers and employees, while providing superior returns to investors.